Francesco Facciolo

Prof. Francesco Facciolo

Thoracic Surgery Department, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2018 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
LCLuigino Calzetta
Luigino Calzetta
PRPaola Rogliani
Paola Rogliani
Francesco FaccioloFrancesco Facciolo
Francesco Facciolo
BRBarbara Rinaldi
Barbara Rinaldi
MCMario Cazzola
Mario Cazzola
MMMaria Gabriella Matera
Maria Gabriella Matera
N-Acetylcysteine (NAC) reduces the risk of exacerbation of chronic obstructive pulmonary disease (COPD). Although NAC also has anti-inflammatory activity, the detailed mechanism leading to its protective role remains to be elucidated. We tested the impact of NAC against the effects of lipopolysaccharide (LPS) in an ex vivo model of COPD exacerbation, and investigated the role of neurokinin A (NKA) in this context. Isolated airways from COPD patients were incubated overnight with LPS (100 ng/ml). NAC was tested at concentrations resembling the plasma levels elicited by oral administration of NAC at 200 mg/day (very low dose), 600 mg/day (low dose) and 1.200 mg/day (high dose). NAC at high concentrations normalized the peroxidase activity, H2O2, malondialdehyde (MDA), nitric oxide, glutathione (GSH), total antioxidant capacity (TAC), and interleukin 6 (IL-6) (overall change 34.32% ± 4.22%, P < 0.05 vs. LPS-treated). NAC at low concentrations modulated peroxidase activity, H2O2, MDA, GSH, TAC, and IL-6 (overall change 34.88% ± 7.39%, P < 0.05 vs. LPS-treated). NAC at very-low concentrations was effective on peroxidase activity, H2O2, GSH, and IL-6 (overall change 35.05 ± 7.71%, P < 0.05 vs. LPS-treated). Binary logistic regression analysis indicated that the modulatory effect of NAC on NKA levels was associated with a reduction of pro-oxidant factors and IL-6, and selectively blocking the NK2 receptor abolished such an association. This study demonstrates that, along with its well-known antioxidant activity, the protective effect of NAC against the detrimental effect of LPS is due to the modulation of NKA and IL-6 levels.

13 April 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
FGFilippo Tommaso Gallina
Filippo Tommaso Gallina
RTRiccardo Tajè
Riccardo Tajè
DFDaniele Forcella
Daniele Forcella
FCFelicita Corzani
Felicita Corzani
VCVirna Cerasoli
Virna Cerasoli
Francesco FaccioloFrancesco Facciolo
Francesco Facciolo
Background: While the thoracotomy approach was considered the gold standard until two decades ago, robotic surgery has increasingly strengthened its role in lung cancer treatment, improving patients’ peri-operative outcomes. In this study, we report our experience in robotic lobectomy for early-stage non-small cell lung cancer, with particular attention to oncological outcomes and nodal upstaging rate. Methods: We retrospectively reviewed patients who underwent lobectomy and radical lymphadenectomy at our Institute between 2016 and 2020. We selected 299 patients who met the inclusion criteria of the study. We analyzed the demographic features of the groups as well as their nodal upstaging rate after pathological examination. Then, we analyzed disease-free and overall survival of the entire enrolled patient population and we compared the same oncological outcomes in the upstaging and the non-upstaging group. Results: A total of 299 patients who underwent robotic lobectomy were enrolled. After surgery, 55 patients reported nodal hilar or mediastinal upstaging. The 3-year overall survival of the entire population was 82.8%. The upstaging group and the non-upstaging group were homogeneous for age, gender, smoking habits, clinical stage, tumor site, tumor histology. The non-upstaging group had better OS (p = 0.004) and DFS (p < 0.0001). Conclusion: Our results show that robotic surgery is a safe and feasible approach for the treatment of early-stage NSCLC, especially for its accuracy in mediastinal lymphadenectomy. The oncological outcomes were encouraging and consistent with previous findings.

20 May 2008 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
GSGiorgio V. Scagliotti
Giorgio V. Scagliotti
UPUgo Pastorino
Ugo Pastorino
JVJ. F. Vansteenkiste
J. F. Vansteenkiste
LSLorenzo Spaggiari
Lorenzo Spaggiari
Francesco FaccioloFrancesco Facciolo
Francesco Facciolo
VTV. Torri
V. Torri
7508 Background: This phase III study tested the hypothesis whether 3 preoperative cycles of gemcitabine-cisplatin followed by radical surgery provides a reduction in the risk of progression compared with surgery alone in patients (pts) with stage IB- IIIA NSCLC. Methods: Chemotherapy naive pts with clinical stage T2N0, T1–2N1, or T3N0–1 received either preoperatively cisplatin (75 mg/m2, day 1) and gemcitabine (1,250 mg/m2, days 1&8), q3week followed by surgery (C+S) or surgery alone (S). In 2004 the enrollment was closed early after the inclusion of 270 out of 700 planned pts because investigators felt it unethical to complete the study treating patients with surgery alone due to positive adjuvant studies. Results: From September 2000 to December 2004, 141 pts were randomized to S and 129 to C+S. Median age was 63/61 years, and most of pts were male (89%/78%). Stage IB/IIA disease was reported in 55% and 46%, respectively. The commonest histology was squamous cell carcinoma (45%/37%) followed by adenocarcinoma (30%/33%). In C+S arm, 86% of patients received all 3 cycles of chemotherapy. Surgery was performed in 96% of pts in the S arm and in 85% of C+S arm. Response rate to chemotherapy was 35% (95%CI 26–44). Progression of neoplastic disease during chemotherapy was reported in 5.5% of pts. As of November 2007, 55% of the progressions occurred. The 3-yr progression-free survival (PFS) rate was 48% in S (95%CI: 38% - 56%) and 53% in C+S (95%CI: 43% - 61%) (p= 0.11, log-rank test). The overall 3-year survival rate was 60% in S (95% CI: 51% - 68%) and 67% in C+S (95% CI 58% - 75%) (p= 0.053). Eight deaths related to study drug or procedure were observed during the study (6 in S, 2 in C+S). Conclusions: This prematurely closed phase III study in early-stage NSCLC indicates the efficacy outcome estimates in the range of those reported from other neoadjuvant trials in the same setting of patients.

18 January 2024 in Cancers
Verified
Journal Article
Open access
PDF file
ESElisa Sicolo
Elisa Sicolo
CZCarmelina Cristina Zirafa
Carmelina Cristina Zirafa
GRGaetano Romano
Gaetano Romano
JBJury Brandolini
Jury Brandolini
Angela De PalmaAngela De Palma
Angela De Palma
FMFranca M.A. Melfi
Franca M.A. Melfi
Thymectomy is the gold standard in the treatment of thymic neoplasm and plays a key role in the therapeutic path of myasthenia gravis. For years, sternotomy has been the traditional approach for removing anterior mediastinal lesions, although the robotic thymectomy is now widely performed. The literature is still lacking in papers comparing the two approaches and evaluating long-term oncological and neurological outcomes. This study aims to analyze the postoperative results of open and robotic thymectomy for thymic neoplasms in myasthenic patients. Surgical, oncological and neurological data of myasthenic patients affected by thymic neoplasms and surgically treated with extended thymectomy, both with the open and the robotic approach, in six Italian Thoracic Centers between 2011 and 2021 were evaluated. A total of 213 patients were enrolled in the study: 110 (51.6%) were treated with the open approach, and 103 (48.4%) were treated with robotic surgery. The open surgery, compared with the robotic, presented a shorter operating time (p < 0.001), a higher number of postoperative complications (p = 0.038) and longer postoperative hospitalization (p = 0.006). No other differences were observed in terms of surgical, oncological or neurological outcomes. The robotic approach can be considered safe and feasible, comparable to the open technique, in terms of surgical, oncological and neurological outcomes.

13 April 2022 in Cancers
Verified
Journal Article
Open access
PDF file
FGFilippo Tommaso Gallina
Filippo Tommaso Gallina
Luca BertolacciniLuca Bertolaccini
Luca Bertolaccini
DFDaniele Forcella
Daniele Forcella
SMShehab Mohamed
Shehab Mohamed
SCSerena Ceddia
Serena Ceddia
Francesco FaccioloFrancesco Facciolo
Francesco Facciolo
Next-generation sequencing has become a cornerstone in clinical oncology practice and is recommended for the appropriate use of tailored therapies in NSCLC. While NGS has already been standardised in advanced-stage NSCLC, its use is still uncommon in the early stages. The recent approval of Osimertinib for resected EGFR-mutated NSCLC in an adjuvant setting has launched the hypothesis that other targeted therapies used in metastatic patients can also lead to improved early-stage outcomes of NSCLC. The impact of molecular biomarkers on the prognosis of patients undergoing radical surgery for NSCLC is still unclear. Notably, the heterogeneous populations included in the studies that analysed surgical patients could be the main reason for these results. In this review, we report the most important studies that analysed the impact of principal molecular biomarkers on the survival outcomes of patients who underwent radical surgery for NSCLC.

28 January 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
LCLuigino Calzetta
Luigino Calzetta
Alfredo ChettaAlfredo Chetta
Alfredo Chetta
Marina AielloMarina Aiello
Marina Aiello
AFAnnalisa Frizzelli
Annalisa Frizzelli
JOJosuel Ora
Josuel Ora
PRPaola Rogliani
Paola Rogliani
The BNT162b2 COVID-19 vaccine is composed of lipid-nanoparticles (LNP) containing the mRNA that encodes for SARS-CoV-2 spike glycoprotein. Bronchospasm has been reported as an early reaction after COVID-19 mRNA vaccines in asthmatic patients. The aim of this study was to investigate the acute impact of BNT162b2 in a human ex vivo model of severe eosinophilic asthma. Passively sensitized human isolated bronchi were challenged with the platelet-activating factor to reproduce ex vivo the hyperresponsiveness of airways of patients suffering from severe eosinophilic asthma. BNT162b2 was tested on the contractile sensitivity to histamine and parasympathetic activation via electrical field stimulation (EFS); some experiments were performed after mRNA denaturation. BNT162b2 increased the resting tone (+11.82 ± 2.27%) and response to histamine in partially contracted tissue (+42.97 ± 9.64%) vs. the control (p < 0.001); it also shifted the concentration-response curve to histamine leftward (0.76 ± 0.09 logarithm) and enhanced the response to EFS (+28.46 ± 4.40%) vs. the control. Denaturation did not significantly modify (p > 0.05) the effect of BNT162b2. BNT162b2 increases the contractile sensitivity to histamine and parasympathetic activation in hyperresponsive airways, a detrimental effect not related to the active component but to some excipient. A possible candidate for the bronchospasm elicited by BNT162b2 could be the polyethylene glycol/macrogol used to produce LNP.